In BC cell lines, the upregulation of RPS6KA2 (RSK3) or RPS6KA6 (RSK4) promoted resistance to a PI3K inhibitor, and an RSK inhibitor in addition to PI3K inhibitor could overcome the resistance [138]. Here, RPS6KA6 is linked to breast cancer.